FI105192B - Menetelmä ihmisen interleukiini-3:n mutanttien aikaansaamiseksi - Google Patents

Menetelmä ihmisen interleukiini-3:n mutanttien aikaansaamiseksi Download PDF

Info

Publication number
FI105192B
FI105192B FI903996A FI903996A FI105192B FI 105192 B FI105192 B FI 105192B FI 903996 A FI903996 A FI 903996A FI 903996 A FI903996 A FI 903996A FI 105192 B FI105192 B FI 105192B
Authority
FI
Finland
Prior art keywords
leu
asn
thr
ala
aac
Prior art date
Application number
FI903996A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI903996A0 (fi
Inventor
Leen Robert Willem Van
Lambertus Christiaan Dorssens
Original Assignee
Dsm Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26121243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI105192(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dsm Nv filed Critical Dsm Nv
Publication of FI903996A0 publication Critical patent/FI903996A0/fi
Application granted granted Critical
Publication of FI105192B publication Critical patent/FI105192B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5403IL-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI903996A 1989-08-14 1990-08-13 Menetelmä ihmisen interleukiini-3:n mutanttien aikaansaamiseksi FI105192B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP89202082 1989-08-14
EP89202082 1989-08-14
EP89202331 1989-09-14
EP89202331 1989-09-14

Publications (2)

Publication Number Publication Date
FI903996A0 FI903996A0 (fi) 1990-08-13
FI105192B true FI105192B (fi) 2000-06-30

Family

ID=26121243

Family Applications (1)

Application Number Title Priority Date Filing Date
FI903996A FI105192B (fi) 1989-08-14 1990-08-13 Menetelmä ihmisen interleukiini-3:n mutanttien aikaansaamiseksi

Country Status (17)

Country Link
EP (2) EP0810285A3 (ja)
JP (1) JP3192416B2 (ja)
AT (1) ATE154638T1 (ja)
AU (1) AU636641B2 (ja)
CA (1) CA2023246C (ja)
DD (1) DD301724A9 (ja)
DE (1) DE69030937T2 (ja)
DK (1) DK0413383T3 (ja)
ES (1) ES2106017T3 (ja)
FI (1) FI105192B (ja)
GR (1) GR3024679T3 (ja)
HU (1) HUT54411A (ja)
IE (2) IE980055A1 (ja)
IL (1) IL95350A0 (ja)
NO (1) NO301481B1 (ja)
NZ (1) NZ234869A (ja)
PT (1) PT94992B (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2120707A1 (en) * 1991-10-07 1993-04-15 Mathew A. Vadas Human il-3 variants
US6413509B1 (en) 1992-11-24 2002-07-02 S. Christopher Bauer Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
US6403076B1 (en) 1992-11-24 2002-06-11 S. Christopher Bauer Compositions for increasing hematopoiesis with interleukin-3 mutants
US6361976B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US6361977B1 (en) * 1992-11-24 2002-03-26 S. Christopher Bauer Methods of using multivariant IL-3 hematopoiesis fusion protein
US6153183A (en) * 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US5772992A (en) * 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5604116A (en) 1992-11-24 1997-02-18 G. D. Searle & Co. Interleukin-3 (IL-3) multiple mutation polypeptides, recombinant production of the same, and corresponding therapeutic methods
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
CA2168261A1 (en) * 1993-07-28 1995-02-09 Mathew Alexander Vadas Haemopoietic growth factor antagonists
US6465616B1 (en) 1994-04-08 2002-10-15 Bresagen Limited Interleukin-5 antagonist
US6017523A (en) * 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
JP4735670B2 (ja) * 2008-06-11 2011-07-27 富士ゼロックス株式会社 プリント基板および画像処理装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR871029B (en) 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
EP0790307A1 (en) 1986-12-16 1997-08-20 Gist-Brocades B.V. Molecular cloning and expression of human IL-3
WO1988004691A1 (en) 1986-12-16 1988-06-30 Gist-Brocades N.V. Molecular cloning and expression of human il-3
AU1496688A (en) * 1987-01-20 1988-08-10 Immunex Corporation Human interleukin-3 proteins
US4743264A (en) * 1987-02-05 1988-05-10 Sherva Parker Carole J External prothesis with magnetic field
OA09736A (en) * 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".

Also Published As

Publication number Publication date
DK0413383T3 (da) 1997-07-07
EP0413383B1 (en) 1997-06-18
CA2023246A1 (en) 1991-02-15
EP0413383A1 (en) 1991-02-20
EP0810285A3 (en) 1998-07-08
NO903544D0 (no) 1990-08-13
NZ234869A (en) 1991-12-23
IE980055A1 (en) 2000-02-23
ES2106017T3 (es) 1997-11-01
ATE154638T1 (de) 1997-07-15
JPH0420295A (ja) 1992-01-23
DE69030937T2 (de) 1997-10-09
GR3024679T3 (en) 1997-12-31
PT94992A (pt) 1991-04-18
DD301724A9 (de) 1993-08-12
FI903996A0 (fi) 1990-08-13
HUT54411A (en) 1991-02-28
AU6096090A (en) 1991-02-14
PT94992B (pt) 1997-09-30
CA2023246C (en) 2002-02-19
DE69030937D1 (de) 1997-07-24
NO903544L (no) 1991-02-15
NO301481B1 (no) 1997-11-03
IE902921A1 (en) 1991-02-27
AU636641B2 (en) 1993-05-06
JP3192416B2 (ja) 2001-07-30
EP0810285A2 (en) 1997-12-03
IL95350A0 (en) 1991-06-30

Similar Documents

Publication Publication Date Title
FI105192B (fi) Menetelmä ihmisen interleukiini-3:n mutanttien aikaansaamiseksi
AU632372B2 (en) Fusion proteins comprising gm-csf and il-3
JP3115561B2 (ja) 白血球を増加させるための医薬組成物の製造方法
US5108910A (en) DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5516512A (en) N- and C-terminal truncation and deletion mutants of human interleukin-3
JP3507507B2 (ja) 非免疫原性ペプチドを介して結合されたインターフェロン―αと免疫グロブリンとのハイブリッド
US5073627A (en) Fusion proteins comprising GM-CSF and IL-3
JPH10502801A (ja) 多重変異il−3造血機能性融合タンパク質
JPH08503489A (ja) インターロイキン−3(il−3)突然変異ポリペプチド
AU606585B2 (en) Human granulocyte-macrophage colony stimulating factor-like polypeptides and processes for producing them in high yields in microbial cells
HU204890B (en) Process for producing human interleukin-3 and its muteins
JPH06133793A (ja) ミュレル管抑制物質様ポリペプチドおよびその製造方法
AU5821690A (en) Nonglycosylated human interleukin-3 analog proteins
WO1990001039A1 (en) Nonglycosylated human interleukin-3 compositions
WO1997012977A1 (en) Novel g-csf receptor agonists
WO1992013548A1 (en) Method of inhibiting replication of hiv in macrophages
JP2660332B2 (ja) ヒトm−csfの製造方法
HU209147B (en) Method for producing stimulating factor of human granulocytae colony
IE871727L (en) Novel family of primate il3-like hematopoietic growth¹factors.

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: DSM N.V.

MM Patent lapsed

Owner name: DSM N.V.